|
Variables
|
Patients No. (%)
|
Deaths No. (%)
|
MST (Months)
|
Log-rank P
a
|
|---|
|
Age
| | | | |
|
≤62 years
|
111 (49.3)
|
72 (46.5)
|
25.6
|
0.117
|
|
>62 years
|
114 (50.7)
|
83 (53.5)
|
21.1
| |
|
Gender
| | | | |
|
Female
|
102 (45.3)
|
65 (41.9)
|
26.7
|
0.036
|
|
Male
|
123 (54.5)
|
90 (58.1)
|
22.3
| |
|
Ethnicity
| | | | |
|
White
|
162 (72.0)
|
117 (75.5)
|
23.5
|
0.827
|
|
Non-White
|
63 (28.0)
|
38 (24.5)
|
22.3
| |
|
Smokeb
| | | | |
|
Ever
|
205 (91.5)
|
143 (92.9)
|
23.4
|
0.457
|
|
Never
|
19 (8.5)
|
11 (7.1)
|
21.1
| |
|
Histology
| | | | |
|
Adenocarcinoma
|
79 (35.1)
|
48 (31.0)
|
27.3
|
0.092
|
|
Squamous cell
|
71 (31.6)
|
51 (32.9)
|
23.2
| |
|
Others b
|
75 (33.3)
|
56 (36.1)
|
19.0
| |
|
KPSc
| | | | |
|
90-100
|
51 (25.4)
|
34 (22.7)
|
25.1
|
0.405
|
|
80
|
118 (58.7)
|
90 (60.0)
|
22.1
| |
|
<80
|
32 (15.9)
|
26 (17.3)
|
21.1
| |
|
Tumor stage c
| | | | |
|
T0-2
|
127 (57.2)
|
81 (52.3)
|
26.9
|
0.010
|
|
T3-4
|
95 (42.8)
|
74 (47.7)
|
19.2
| |
|
Node status c
| | | | |
|
N0-1
|
59 (26.7)
|
35 (22.6)
|
29.0
|
0.023
|
|
N2-3
|
162 (73.3)
|
120 (77.4)
|
20.7
| |
|
Chemotherapy
| | | | |
|
Yes
|
163 (72.4)
|
113 (72.9)
|
26.9
|
0.407
|
|
No
|
62 (27.6)
|
42 (27.1)
|
22.1
| |
|
Radiotherapy dosed
| | | | |
|
≤63.0 Gy
|
115 (51.1)
|
77 (49.7)
|
22.7
|
0.706
|
|
>63.0 Gy
|
110 (48.9)
|
78 (50.3)
|
25.1
| |
- MST: median survival time; KPS: Karnofsky's performance scores
-
a Log-rank test.
-
b Others include large cell, undifferentiated and mixed-cell carcinomas.
-
c Some missing data.
-
dThe median radiotherapy dose is 63 Gy.
